5-bromo-6-methylindan | 136708-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-bromo-6-methylindan
• 英文别名: 6-Brom-5-methyl-indan；5-bromo-6-methyl-2,3-dihydro-1H-indene
• CAS: 136708-08-2
• 化学式: C₁₀H₁₁Br
• 分子量: 211.101
• InChiKey: ZFGBNDLGACYVBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  5-甲基-2,3-二氢-1H-茚 在 溴 、 碘 作用下， 生成 5-bromo-6-methylindan
  参考文献：
  名称：

  Nair,P.M. et al., Indian Journal of Chemistry, 1971, vol. 9, p. 549 - 558

  摘要：

  DOI：

文献信息

• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：Whitten Jeffrey P.

  公开号：US20110263612A1

  公开（公告）日：2011-10-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或症状。
• HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF
  申请人：Japan Tobacco, Inc.

  公开号：EP1953147A1

  公开（公告）日：2008-08-06

  The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient: wherein Q1 is -N=, etc., Q2 is -N-, etc., Q3 is -N=, etc., Q4 is -N-, etc., Q5 is -N-, etc., R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.

  本发明旨在提供一种具有HCV进入抑制活性的新型杂环化合物及其药物用途。本发明提供了一种治疗丙型肝炎的治疗剂，其包括以下式[1]所表示的杂环化合物或其药学上可接受的盐作为活性成分：其中Q1为-N=等，Q2为-N-等，Q3为-N=等，Q4为-N-等，Q5为-N-等，R1为氢原子等，R2为氢原子等，环A为单环芳基，可选地具有取代基等，环B为单环芳基，可选地具有取代基等。
• Hsp90 Inhibitors
  申请人：Chiosis Gabriela

  公开号：US20120208806A1

  公开（公告）日：2012-08-16

  The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease.

  本申请提供了一些化合物，可用于抑制Hsp90，并因此用于治疗疾病。
• PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：US20160310497A1

  公开（公告）日：2016-10-27

  The present application provides substituted purine derivatives and related compounds of the formulas shown. These compounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z 1 -Z 3 , X a -X c , X 2 , X 4 , Y and R are as defined in the specification.
• US8980629B2
  申请人：——

  公开号：US8980629B2

  公开（公告）日：2015-03-17